Company intelligence / Profile preview
Vascarta
Summit, New Jersey, United Statesvascarta.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
VAS101, a patented topical curcumin formulation using transdermal technology, has shown promising preclinical results in reducing pain, stabilizing red blood cells, and lowering inflammation in sickle cell disease. It is currently being evaluated in Phase 1 clinical trials for both sickle cell disease and osteoarthritis. The FDA granted Orphan Drug Designation to Vasceptor® (VAS101) for sickle cell disease in June 2025. Preclinical studies also support potential benefits across other chronic inflammatory conditions.
- Therapeutic areas
- OncologyRheumatologyNeurologyHematology
- Modalities
- Small moleculeTopical/transdermal drug deliveryCurcumin-based therapyPotential for chemotherapeutic conjugates (curcumin-drug hybrids)
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →03
Partnerships
Foundation for Sickle Cell Disease Research [FSCDR] – Clinical trial site/collaborator
Beyond the preview
Go deeper on Vascarta.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Vascarta.